RxDoctor Payments Data

Tyler Christensen, DO

Emergency Medicine · Springfield, MANPI 1811254360

Payments from drug & device makers

$654in general payments, 2019–2025

Across 23 payments — averaging $28.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$494
  • Smith+Nephew$42
  • Integra Lifesciences Corporation$38
  • Koya Medical, Inc.$26
  • Solventum Corporation$24
  • Paratek Pharmaceuticals, Inc.$18
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$654100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Organogenesis Inc.15$494
Smith+Nephew2$42
Integra Lifesciences Corporation2$38
Koya Medical, Inc.1$26
Solventum Corporation1$24
Paratek Pharmaceuticals, Inc.1$18
180 Medical, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$654 in reported general payments places this provider in the 90th percentile of 1,429 emergency medicine providers in Massachusetts.

See all emergency medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$57,261
Medicare patients
302
Services billed
652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.20$15,514
Cefpodoxime Proxetil15$788
Doxycycline Monohydrate37$487
Gentamicin Sulfate12$409
Cephalexin17$303
CefuroximeCefuroxime Axetil14$209
Mupirocin19$170
Betamethasone Valerate14$167
Oxycodone Hcl26$129
Lidocaine-PrilocaineLidocaine/Prilocaine13$121
Prednisone14$76
Levofloxacin14$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$42$15,51420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,429 emergency medicine providers in Massachusetts.

Other emergency medicine in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →